The acute reduction of low-density lipoprotein (LDL) cholesterol obtained by LDL-apheresis allows the role of the high level of circulating LDL on lipoprotein metabolism in heterozygous familial hypercholesterolemia (heterozygous FH) to be addressed. We studied apolipoprotein B (apoB) kinetics in five heterozygous FH patients before and the day after an apheresis treatment using endogenous labe...

Seven moderately hypercholesterolemic subjects were studied before and after 10 weeks of simvastatin therapy (20 mg/day). Therapy reduced low density lipoprotein (LDL) cholesterol by 39% (p < 0.001), whereas high density lipoprotein and very low density lipoprotein (VLDL) cholesterol were unchanged. Apolipoprotein (apo) B-containing lipoproteins were divided into VLDL1 (Sf 60-400), VLDL2 (Sf 20...

BACKGROUND Cardiovascular disease risk can be estimated in part on the basis of the plasma lipoprotein profile. Analysis of lipoprotein subclasses improves the risk evaluation, but the traditional methods are very time-consuming. Novel, rapid, and productive methods are therefore needed. METHODS We obtained plasma samples from 103 fasting people and determined the plasma lipoprotein subclass ...

BACKGROUND Lipoproteins may contribute to diabetic nephropathy. Nuclear magnetic resonance (NMR) can quantify subclasses and mean particle size of very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL), and LDL particle concentration. The relationship between detailed lipoprotein analyses and diabetic nephropathy is of interest. METHODS In a cro...

Very low-density lipoprotein (VLDL) receptor is a member of the low-density lipoprotein (LDL) receptor family. It binds triglyceride rich lipoprotein (TGRL) but not LDL, because it recognizes apolipoprotein (apo)E only but not apoB. The VLDL receptor functions as a peripheral lipoprotein receptor in concert with lipoprotein lipase (LPL) in heart, muscle, adipose tissue and macrophages. In contr...

Lipoprotein monitoring is desirable in the management of medical conditions such as atherosclerotic cardiovascular disease and coronary artery disease, which controlling concentration these chylomicrons crucial. Current clinical methods are complex present poor reproducibility between laboratories. For reasons, recent guidelines discard assessment low-density lipoprotein cholesterol (LDL-C) a r...

Background: Dyslipidemia is a lipid metabolism disorder that causes changes in plasma lipoprotein function and/or levels of Triglycerides (TG), total cholesterol (TC), Low-Density Lipoprotein (LDL), and High-Density (HDL). Administration Medium Chain Triglyceride (MCT) non-pharmacological therapy effectively improves profiles reduces the risk dyslipidemia. Objectives: This study aimed to conduc...

BACKGROUND Small dense low-density lipoprotein (sd-LDL) is an atherogenic lipoprotein closely associated with an increased risk of cardiovascular diseases. However, a precise analysis of the actual amount of sd-LDL-cholesterol (sd-LDL-C) in patients with metabolic syndrome (MS) has not been performed. METHODS AND RESULTS Among 214 patients enrolled in the present study, 101 patients (47%) met...

Lipoprotein oxidation is a key early stage in the development of atherosclerosis. Oxidation of low-density lipoprotein (LDL) is initiated by both enzyme-mediated and non-enzymic mechanisms in vivo, and oxidized LDL has many atherogenic properties. Oxidation of LDL in vivo is likely to be influenced by local environmental factors, such as pH. The composition of LDL is also important, including s...

The low density lipoprotein particle is the major transporter of cholesterol around the body and has been shown to be a strong independent risk factor for atherosclerotic events. This review discusses the normal and abnormal metabolism of low density lipoprotein (LDL). Mechanisms by which LDL causes atherosclerosis are discussed with particular reference to the importance of alteration in LDL c...